Neovasc Inc is not compliant with Shariah. The company’s financials fail all the five standards we check against.
Ad
NVCN – Neovasc Inc
Not Compliant
—X—
$16,622,911
Market cap
76.84%
Revenue Growth
-
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✗
| Debt ÷ Market cap (MC) | 79.78% | ✗ |
| Non-Compliant Assets ÷ MC | 0.26% | ✓ |
| Impure Income (incl. Interest) | 21.67% | ✗ |
| Impure Income | % |
| Interest Income | 21.67% |
| Total | 21.67% |
S&P
S&P ✗
| Debt ÷ 36 mo MC | 38.33% | ✗ |
| Cash ÷ 36 mo MC | 148.93% | ✗ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✗
| Debt ÷ 24 mo MC | 34.96% | ✗ |
| Cash ÷ 24 mo MC | 135.86% | ✗ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 18.81% | ✓ |
| Cash ÷ Assets | 73.08% | ✗ |
| Cash&AR ÷ Assets | 73.08% | ✗ |
| Impure Income (incl. Interest) | 21.67% | ✗ |
| Impure Income | % |
| Interest Income | 21.67% |
| Total | 21.67% |
MSCI
MSCI ✗
| Debt ÷ Assets | 18.81% | ✓ |
| Cash ÷ Assets | 73.08% | ✗ |
| Cash&AR ÷ Assets | 73.08% | ✗ |
Ad
N/A
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Total Analysts: 0
Company Profile
Neovasc Inc. is a Canada-based specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses